Editorial: Anti-MDA5-Positive Dermatomyositis
- PMID: 35712109
- PMCID: PMC9195172
- DOI: 10.3389/fmed.2022.941370
Editorial: Anti-MDA5-Positive Dermatomyositis
Keywords: anti-MDA5; antifibrotic agent; dermatomyositis; immunosuppressive therapy; interstitial lung disease; type 1 interferon pathway.
Conflict of interest statement
TG received speaking fees from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, MBL, Nippon Shinyaku, and Ono Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Anti-MDA5-Positive Dermatomyositis
References
-
- Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M, et al. . helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. (2009) 60:2193–200. 10.1002/art.24621 - DOI - PubMed
-
- Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. . Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. (2012) 64:3736–40. 10.1002/art.34657 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources